Theravance Biopharma, Inc.
TBPH
$17.06
$0.000.00%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 312.92% | 296.36% | 287.70% | 159.40% | 128.54% |
| Total Depreciation and Amortization | 0.56% | -4.54% | -7.89% | -13.28% | -7.82% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 407.44% | -75.01% | -64.50% | -92.92% | -89.69% |
| Change in Net Operating Assets | -109.32% | 111.76% | 491.85% | 6,669.48% | 10,786.30% |
| Cash from Operations | -78.07% | 726.36% | 2,167.98% | 2,221.55% | 2,891.56% |
| Capital Expenditure | 96.65% | 82.57% | 87.35% | 72.65% | 71.03% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -1,413.52% | -418.73% | -934.19% | -2,659.57% | -150.27% |
| Cash from Investing | -1,364.34% | -421.86% | -957.08% | -2,110.98% | -155.18% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 930.77% | 60.61% | 29.49% | -25.28% | -64.86% |
| Repurchase of Common Stock | -359.56% | -296.91% | -29.96% | 92.26% | 96.42% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -302.82% | -387.52% | -30.08% | 93.52% | 96.72% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -126.39% | 212.59% | 7,537.59% | 413.40% | 497.60% |